Substantiation of conditions for determination of related substances in bisoprolol fumarate by HPLC

The article summarizes the results of information analysis of bisoprolol fumarate synthesis methods which differ in the number of stages and in raw materials used, and are associated with the major identified impurities A, E and G, according to the European Pharmacopoeia (Ph. Eur.). The authors performed a comparative analysis of the test procedures described in manufacturers’ quality standards, Ph. Eur. and United States Pharmacopoeia (USP) and analyzed the results of comparative experimental studies. It was shown that the implementation of the Ph. Eur. test method for related impurities according to «Bisoprolol fumarate» monograph demonstrated a high resolution between the main peak (of bisoprolol) and those of impurities A, E and G. Whereas the performance of the chromatographic system suitability testing according to the USP monograph failed to produce complete resolution between the peaks of bisoprolol and the impurities. The authors investigated the possibility of using a propranolol hydrochloride reference standard to assess the system resolution. The authors identified the conditions for determination of related substances in bisoprolol fumarate, selected chromatographic columns, proposed chromatographic system suitability criteria, including resolution between the peaks of bisoprolol and propranolol, and established limits for impurities.

бисопролола фумарат, схема синтеза, родственные примеси, высокоэффективная жидкостная хроматография, оптимальные условия определения, критерии пригодности системы, bisoprolol fumarate, synthesis method, related substances, high-performance liquid chromatography, ideal conditions for determination, system suitability criteria

1. Bisoprolol. Patient information, use and formula. Register of medicines marketed in Russia [Internet]. 2017 [cited 2017 June 16]. Available from: https://goo.gl/PY254m (in Russian).

2. Order of the Government of the Russian Federation of 28.12.2016, No. 2885-r «On the approval of the list of vital and essential drugs for 2017». Available from: https://goo.gl/vgvPzL (in Russian).

3. Romanov BK, Olefir YuV, Merkulov VA, Pegova YuO. The revision of the restrictive lists of medicinal products. Safety and Risks of Pharmacotherapy 2016; (1): 5–9 (in Russian).

4. 19th Model List of Essential Medicines of the World Health Organization (WHO) (April 2015) [Internet]. 2017 [cited 2017 June 16]. Available from: http://www.apteka.ua/article/333051 (in Russian).

5. Mironov AN, Sakaeva IV, Sakanyan EI, Bunyatyan ND, Kovaleva EL, Mit’kina LI, Shemeryankina TB, Yashkir VA. Reference standards in international and domestic pharmaceutical analysis. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2012; (3): 56–60 (in Russian).

6. Kovaleva EL, Bagirova VL, Shanazarov KS. Developing methodological approaches to standartization of pharmaceuticals. Pharmaceutical Chemistry Journal 2010; 44(1): 35–42 (in Russian).

7. European Pharmacopoeia Online. European Directorate for the Quality of Medicines [Internet]. 2017 [cited 2017 June 16]. Available from: http://online.edqm.eu/.

8. United States Pharmacopeia. 39th ed. [Internet]. 2017 [cited 2017 June 16]. Available from: http://www.uspnf.com/uspnf.

9. Mit’kina LI, Kovaleva EL. Approaches to evaluation of analytical methods suitability when performing medicines quality evaluation. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2012; (2): 6–9 (in Russian).